JOHNSON & JOHNSON - JNJ
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | EVP, WWC. Innovative Medicine | M | D | 15,000.0 | 0.0 | 0.0 | 28,712.0 | View | |
| Aug 18, 2026 | EVP, WWC. Innovative Medicine | S | D | 15,000.0 | 263.36 | 3,950,400.0 | 194,451.0 | View | |
| Aug 18, 2026 | EVP, WWC. Innovative Medicine | M | A | 15,000.0 | 115.67 | 1,735,050.0 | 209,451.0 | View | |
| Aug 14, 2026 | CEO and Chairman of the Board | M | D | 123,291.0 | 0.0 | 0.0 | 0.0 | View | |
| Aug 14, 2026 | CEO and Chairman of the Board | S | D | 102,315.0 | 261.0 | 26,704,215.0 | 275,967.0 | View | |
| Aug 14, 2026 | CEO and Chairman of the Board | S | D | 20,976.0 | 262.0 | 5,495,712.0 | 378,282.0 | View | |
| Aug 14, 2026 | CEO and Chairman of the Board | M | A | 123,291.0 | 115.67 | 14,261,069.97 | 399,258.0 | View | |
| Aug 07, 2026 | CEO and Chairman of the Board | S | D | 6,523.0 | 258.739 | 1,687,754.5 | 275,967.0 | View | |
| Aug 07, 2026 | CEO and Chairman of the Board | S | D | 41,957.0 | 258.056 | 10,827,255.59 | 282,490.0 | View | |
| Aug 07, 2026 | EVP, Chief Legal Officer | M | D | 9,344.0 | 0.0 | 0.0 | 0.0 | View | |
| Aug 07, 2026 | EVP, Chief Legal Officer | S | D | 6,574.0 | 255.932 | 1,682,496.97 | 16,994.0 | View | |
| Aug 07, 2026 | EVP, Chief Legal Officer | S | D | 9,344.0 | 257.755 | 2,408,462.72 | 23,568.0 | View | |
| Aug 07, 2026 | EVP, Chief Legal Officer | M | A | 9,344.0 | 131.94 | 1,232,847.36 | 32,912.0 | View | |
| Jul 21, 2026 | EVP, Global Corp Affairs | M | D | 11,925.0 | 0.0 | 0.0 | 0.0 | View | |
| Jul 21, 2026 | EVP, Global Corp Affairs | M | D | 11,129.0 | 0.0 | 0.0 | 0.0 | View | |
| Jul 21, 2026 | EVP, Global Corp Affairs | S | D | 23,054.0 | 251.266 | 5,792,686.36 | 23,003.0 | View | |
| Jul 21, 2026 | EVP, Global Corp Affairs | M | A | 11,925.0 | 131.94 | 1,573,384.5 | 46,057.0 | View | |
| Jul 21, 2026 | EVP, Global Corp Affairs | M | A | 11,129.0 | 129.51 | 1,441,316.79 | 34,132.0 | View | |
| Jun 12, 2026 | EVP, Chief TO and Risk Officer | M | D | 10,000.0 | 0.0 | 0.0 | 32,965.0 | View | |
| Jun 12, 2026 | EVP, Chief TO and Risk Officer | S | D | 10,000.0 | 241.15 | 2,411,500.0 | 114,287.87 | View | |
| Jun 12, 2026 | EVP, Chief TO and Risk Officer | M | A | 10,000.0 | 115.67 | 1,156,700.0 | 124,287.87 | View | |
| Jun 11, 2026 | — | A | A | 161.09 | 232.79 | 37,499.91 | 6,411.96 | View | |
| Jun 11, 2026 | — | A | A | 134.24 | 232.79 | 31,249.96 | 2,320.82 | View | |
| Jun 11, 2026 | — | A | A | 214.79 | 232.79 | 50,000.03 | 15,791.88 | View | |
| May 04, 2026 | EVP, Innovative Medicine, R&D | M | D | 25,255.0 | 0.0 | 0.0 | 0.0 | View | |
| May 04, 2026 | EVP, Innovative Medicine, R&D | F | D | 11,002.0 | 229.85 | 2,528,809.7 | 24,911.0 | View | |
| May 04, 2026 | EVP, Innovative Medicine, R&D | M | A | 25,255.0 | 0.0 | 0.0 | 35,913.0 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 6,215.09 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 7,730.05 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 12,010.41 | View | |
| Apr 27, 2026 | — | A | A | 1,712.0 | 0.0 | 0.0 | 2,174.07 | View | |
| Apr 27, 2026 | — | A | A | 1,540.0 | 0.0 | 0.0 | 1,540.0 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 21,278.59 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 9,183.61 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 5,359.4 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 15,487.94 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 10,899.17 | View | |
| Apr 27, 2026 | — | A | A | 975.0 | 0.0 | 0.0 | 16,797.74 | View | |
| Mar 12, 2026 | — | A | A | 129.06 | 242.14 | 31,250.1 | 462.07 | View | |
| Mar 12, 2026 | — | A | A | 206.49 | 242.14 | 49,999.97 | 14,512.94 | View | |
| Mar 12, 2026 | — | A | A | 75.26 | 166.1 | 12,500.02 | 14,306.45 | View | |
| Mar 12, 2026 | — | A | A | 154.87 | 242.14 | 37,499.98 | 5,240.09 | View | |
| Mar 03, 2026 | VP Corporate Controller | M | D | 4,075.0 | 0.0 | 0.0 | 0.0 | View | |
| Mar 03, 2026 | VP Corporate Controller | S | D | 4,075.0 | 247.87 | 1,010,070.25 | 23,682.0 | View | |
| Mar 03, 2026 | VP Corporate Controller | M | A | 4,075.0 | 115.67 | 471,355.25 | 27,757.0 | View |